Hsbc Holdings PLC Has $9.94 Million Stock Position in STERIS plc $STE

Hsbc Holdings PLC cut its stake in shares of STERIS plc (NYSE:STE) by 9.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 38,965 shares of the medical equipment provider’s stock after selling 4,094 shares during the period. Hsbc Holdings PLC’s holdings in STERIS were worth $9,943,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of STE. Board of the Pension Protection Fund acquired a new position in STERIS in the 4th quarter worth about $25,000. Harbor Investment Advisory LLC increased its stake in shares of STERIS by 115.4% in the fourth quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 60 shares during the period. Activest Wealth Management raised its holdings in STERIS by 423.8% in the 4th quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 89 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new stake in STERIS during the 4th quarter worth approximately $28,000. Finally, Geneos Wealth Management Inc. boosted its position in STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 104 shares during the period. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Daniel A. Carestio sold 1,374 shares of STERIS stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $212.00, for a total value of $291,288.00. Following the completion of the transaction, the chief executive officer directly owned 63,647 shares of the company’s stock, valued at approximately $13,493,164. This trade represents a 2.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard C. Breeden sold 1,481 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $209.51, for a total value of $310,284.31. Following the completion of the transaction, the director directly owned 38,964 shares in the company, valued at $8,163,347.64. This represents a 3.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 7,328 shares of company stock worth $1,554,051. Company insiders own 1.12% of the company’s stock.

STERIS Stock Down 2.8%

Shares of NYSE STE opened at $209.34 on Thursday. The company has a market capitalization of $20.40 billion, a P/E ratio of 26.40 and a beta of 0.92. STERIS plc has a 52-week low of $195.14 and a 52-week high of $269.44. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.54 and a current ratio of 2.09. The company’s 50 day moving average price is $211.32 and its 200-day moving average price is $230.83.

STERIS (NYSE:STE) last posted its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a return on equity of 14.15% and a net margin of 13.18%.The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same quarter last year, the company earned $2.74 earnings per share. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Equities analysts forecast that STERIS plc will post 11.18 earnings per share for the current year.

STERIS Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 26th. Shareholders of record on Monday, June 8th were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date was Monday, June 8th. STERIS’s dividend payout ratio (DPR) is presently 31.78%.

Analysts Set New Price Targets

STE has been the subject of several recent research reports. Wall Street Zen cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. Piper Sandler reiterated an “overweight” rating and set a $270.00 price target on shares of STERIS in a report on Thursday, May 21st. Weiss Ratings cut shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. Finally, KeyCorp decreased their price objective on STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, STERIS presently has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.